Target Corporation TGT 0.31% shares were up a modest 0.6 percent in early Wednesday trading after the company’s board approved a massive new $5 billion buyback plan. The new plan will begin upon completion of the current $10 billion buyback plan by the end of fiscal 2016.
One of the richest and most respected hedge fund managers in the world has been charged with insider trading.
When a company is already struggling to adapt its brand to a changing market environment, the last thing it needs it to be named at the top of a list of “most hated companies.”
The rise of Snapchat could be bad news for social media stocks, but some should be more scared than others. According to CLSA analyst James Lee, Twitter Inc TWTR 21.42% could be the biggest victim of Snapchat’s success.
Wells Fargo & Co (NYSE: WFC) shareholders were caught completely off guard by the extent of the company’s fraudulent behavior related to its recent $185 million settlement, and now Wells Fargo CEO John Stumpf is getting taken to the woodshed by Senator Elizabeth Warren and others on the Senate Banking Committee.
Apollo Global Management LLC APO 0.44%’s 2016 shopping spree is reportedly still going strong. On Monday, Reuters reported that Apollo is in talks to acquire assets from struggling hospital operatorCommunity Health Systems CYH 0.29%. Community Health Systems currently has a market cap of $1.3 billion and a staggering debt load of $15 billion.
Sonic Corporation SONC 3.22%’s sales and share price have been in a rut the past couple of years, but UBS believes the pain will be short-lived for investors. According to analyst Dennis Geiger, Sonic’s business model and fundamentals remain strong.
For toy makers Hasbro, Inc. HAS 0.54% and Mattel Inc. MAT 0.75%, the holiday shopping season is the most critical time of the year. Although the holiday shopping rush is still a couple of months away, UBS analyst Arpine Kocharyan is reporting some positive preliminary channel checks.
The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year.
PTC Therapeutics, Inc. PTCT 4.79% shares are up another 4.2 percent in early Tuesday trading following a big 20.6 percent Monday gain. The big move in PTC shares has been driven by the FDA’s accelerated approval of Sarepta Therapeutics Inc SRPT 8.45%’s Eteplirsen for treatment of exon 51 skipping amenable Duchenne’s muscular dystrophy.